Form 8-K - Current report:
SEC Accession No. 0001193125-22-282718
Filing Date
2022-11-10
Accepted
2022-11-10 16:42:01
Documents
14
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d392870d8k.htm   iXBRL 8-K 25417
2 EX-99.1 d392870dex991.htm EX-99.1 45536
6 GRAPHIC g392870dsp001.jpg GRAPHIC 8421
  Complete submission text file 0001193125-22-282718.txt   215124

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA etnb-20221110.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20221110_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20221110_pre.xml EX-101.PRE 11705
8 EXTRACTED XBRL INSTANCE DOCUMENT d392870d8k_htm.xml XML 3464
Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 221378013
SIC: 2834 Pharmaceutical Preparations